Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Hepatectomy Combined With Camrelizumab and Apatinib in CNLC Stage IIIb Hepatocellular Carcinoma

NCT05062837 is registered in ClinicalTrials.gov with Guangxi Medical University as lead sponsor.

NCT NCT05062837
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05062837 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Hepatectomy Combined With Camrelizumab and Apatinib in CNLC Stage IIIb Hepatocellular Carcinoma
Lead sponsor
Guangxi Medical University
Phase
Phase 2/3
Overall status
Recruiting
Start date
June 1, 2021
Completion date
December 31, 2026
Enrollment
62 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma